Cervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market – Gilead, Roche, Genentech, Iovance, Bristol-Myers Squibb, Exelixis, Xencor, Merck, EMD Serono, Pfizer, Fusion, AstraZeneca

Advertisement

The cervical cancer market is expected to grow due to factors like an increase in the patient pool, rising awareness of the disease, an increase in healthcare spending across the globe, rising R&D activities, and the expected entry of emerging therapies during the forecast period (2023–2032).

New York, USA, June 22, 2023 (GLOBE NEWSWIRE) — Cervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market – Gilead, Roche, Genentech, Iovance, Bristol-Myers Squibb, Exelixis, Xencor, Merck, EMD Serono, Pfizer, Fusion, AstraZeneca

The cervical cancer market is expected to grow due to factors like an increase in the patient pool, rising awareness of the disease, an increase in healthcare spending across the globe, rising R&D activities, and the expected entry of emerging therapies during the forecast period (2023–2032).

Advertisement

DelveInsight’s Cervical Cancer Market Insights report includes a comprehensive understanding of current treatment practices, cervical cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Cervical Cancer Market Report

  • As per DelveInsight analysis, the cervical cancer market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • According to ASCO, in 2023, an estimated 13,960 women in the United States will be diagnosed with invasive cervical cancer.
  • Leading cervical cancer companies such as Hookipa Biotech GmbH, Gilead Sciences, MacroGenics, Genentech, Inc., Precision Biologics, Inc, Agenus Inc., Hoffmann-La Roche, Nurix Therapeutics, Inc., Iovance Biotherapeutics, Inc., Sensei Biotherapeutics, Inc., AstraZeneca, Daiichi Sankyo Co., Ltd., Verastem, Inc., CRISPR Therapeutics, Advenchen Laboratories, LLC, Totus Medicines, Orano Med LLC, Qurient Co., Ltd., Bristol-Myers Squibb, Exelixis, Xencor, Inc., Transgene, Merck, EMD Serono Research & Development Institute, Inc., Pfizer, Fusion Pharmaceuticals Inc., VM Oncology, LLC, and others are developing novel cervical cancer drugs that can be available in the cervical cancer market in the coming years.
  • Some of the key therapies for cervical cancer treatment include HB-201 IT, Sacituzumab govitecan, MGD019, Atezolizumab, NEO-201 in combination with pembrolizumab, AGEN2034, Tiragolumab + Atezolizumab, De-TIL-0255, LN-145 + pembrolizumab, SNS-101 (anti-VISTA), Trastuzumab deruxtecan, Avutometinib (VS-6766) + defactinib, CTX131, AL3818, TOS-358, ²¹²Pb-DOTAM-GRPR1, Q702, BMS-986340, XB002, XmAb®23104, TG4001 + Avelumab, [225Ac]-FPI-1434 Injection, VMD-928, and others. 

Discover which therapies are expected to grab the major cervical cancer market share @ Cervical Cancer Market Report

Cervical Cancer Overview

Cervical cancer develops in the cells of the cervix, which connects the uterus to the vagina. It typically begins in the transformation zone of the cervix and extends to regional lymph nodes; parametrial invasion is also prevalent. Persistent papillomavirus infection is the leading cause of cervical cancer. HPV is found in 90% of cervical tumors, especially carcinogenic varieties like HPV 16 and 18. As a serious public health hazard in the developed world, it remains a substantial menace.

Cervical cancer is classified into four stages: stage I – cancer that is small, stage II – cancer that is larger and may spread outside of the uterus and cervix, stage III – cancer that spreads to the lower part of the vagina or the pelvis, and stage IV – cancer that has spread outside of the pelvis to organs such as the lungs, bones, or liver. The Papanicolaou (Pap) test has long been the gold standard for cervical cancer screening, lowering the incidence by 60-90% and the death rate by 90%.

Cervical Cancer Epidemiology Segmentation

The cervical cancer epidemiology section provides insights into the historical and current cervical cancer patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The cervical cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Cervical Cancer Incident Cases
  • Cervical Cancer Stage-specific Incident Cases
  • Cervical Cancer Histopathologic Types-specific Incident Cases
  • Cervical Cancer Age-specific Incident Cases

Download the report to understand which factors are driving cervical cancer epidemiology trends @ Cervical Cancer Epidemiological Insights

Cervical Cancer Treatment Market 

Patients in the early stages (IA-IB1) are treated with radical hysterectomy and pelvic lymphadenectomy. Primary chemotherapy and radiation therapy, or CCRT, is used to treat locally advanced cervical cancer (stage IIB2-IVA). Platinum-based treatments such as cisplatin, external beam radiation, and high-dose intracavity brachytherapy are examples of combination therapy. The Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, on September 20, 2021, for adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy.

AVASTIN (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody that binds to and suppresses the biological activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework sections as well as complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab (Avastin) was authorized by the US FDA in August 2014 to treat persistent, recurring, or metastatic cervical cancer. The FDA assessed bevacizumab for the treatment of cervical cancer patients as part of its priority review program.

KEYTRUDA (Pembrolizumab) is the active ingredient in Keytruda, a humanized monoclonal antibody that binds to the programmed cell death – 1 (PD-1) receptor and inhibits its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including anti-tumor immune response. T-cell proliferation and cytokine production are inhibited when the PD-1 ligands, PD-L1 and PD-L2, bind to the PD-1 receptor located on T-cells. In some tumors, PD-1 ligands are upregulated, and signaling through this route can contribute to the suppression of active T-cell immune surveillance of tumors. The therapeutic candidate is now being marketed by Merck Sharp & Dohme for the treatment of patients with recurrent or metastatic cervical cancer who are experiencing disease progression during or after chemotherapy and whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test.

To know more about cervical cancer treatment, visit @ Cervical Cancer Treatment Drugs 

Key Cervical Cancer Therapies and Companies

  • HB-201 IT: Hookipa Biotech GmbH
  • Sacituzumab govitecan: Gilead Sciences
  • MGD019: MacroGenics
  • Atezolizumab: Genentech, Inc.
  • NEO-201 in combination with pembrolizumab: Precision Biologics, Inc
  • AGEN2034: Agenus Inc.
  • Tiragolumab + Atezolizumab: Hoffmann-La Roche
  • De-TIL-0255: Nurix Therapeutics, Inc.
  • LN-145 + pembrolizumab: Iovance Biotherapeutics, Inc.
  • SNS-101 (anti-VISTA): Sensei Biotherapeutics, Inc.
  • Trastuzumab deruxtecan: AstraZeneca/Daiichi Sankyo Co., Ltd.
  • Avutometinib (VS-6766) + defactinib: Verastem, Inc.
  • CTX131: CRISPR Therapeutics
  • AL3818: Advenchen Laboratories, LLC
  • TOS-358: Totus Medicines
  • ²¹²Pb-DOTAM-GRPR1: Orano Med LLC
  • Q702: Qurient Co., Ltd.
  • BMS-986340: Bristol-Myers Squibb
  • XB002: Exelixis
  • XmAb®23104: Xencor, Inc.
  • TG4001 + Avelumab: Transgene/Merck/EMD Serono Research & Development Institute, Inc./Pfizer
  • [225Ac]-FPI-1434 Injection: Fusion Pharmaceuticals Inc.
  • VMD-928: VM Oncology, LLC

Learn more about the FDA-approved drugs for cervical cancer @ Drugs for Cervical Cancer Treatment 

Cervical Cancer Market Dynamics

The cervical cancer market is expected to change in the coming years. Although the usual pap test method of diagnosis has reduced the prevalence by over 75%, additional diagnostic investigations may aid in identifying spread and prognosis, as well as treatment planning, as it remains a serious public health concern even in developed countries. Primary cervical cancer prevention is now possible by immunization with very effective HPV vaccinations. Cervarix, a bivalent HPV virus-like particle vaccination (2vHPV), Gardasil, a quadrivalent HPV virus-like particle vaccine (4vHPV), and Gardasil 9, a nine-valent HPV virus-like particle vaccine (9vHPV) are currently licensed and available. All three vaccines provide protection against HPV 16 and 18.

In addition, increased awareness as a result of initiatives to educate people about diseases is crucial which will propel the cervical cancer market growth.  Moreover, the presence of a strong pipeline is projected to bring about a beneficial impact on the cervical cancer market.

As the cervical cancer pipeline is very robust; many potential therapies are being investigated for the treatment of cervical cancer, and it is safe to predict that the treatment space will significantly impact the cervical cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the cervical cancer market in the 7MM.

However, certain factors may affect the growth of the cervical cancer market. The cervical cancer market growth may be offset by unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists.  In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cervical cancer market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Cervical Cancer Companies Hookipa Biotech GmbH, Gilead Sciences, MacroGenics, Genentech, Inc., Precision Biologics, Inc, Agenus Inc., Hoffmann-La Roche, Nurix Therapeutics, Inc., Iovance Biotherapeutics, Inc., Sensei Biotherapeutics, Inc., AstraZeneca, Daiichi Sankyo Co., Ltd., Verastem, Inc., CRISPR Therapeutics, Advenchen Laboratories, LLC, Totus Medicines, Orano Med LLC, Qurient Co., Ltd., Bristol-Myers Squibb, Exelixis, Xencor, Inc., Transgene, Merck, EMD Serono Research & Development Institute, Inc., Pfizer, Fusion Pharmaceuticals Inc., VM Oncology, LLC, and others
Key Cervical Cancer Therapies HB-201 IT, Sacituzumab govitecan, MGD019, Atezolizumab, NEO-201 in combination with pembrolizumab, AGEN2034, Tiragolumab + Atezolizumab, De-TIL-0255, LN-145 + pembrolizumab, SNS-101 (anti-VISTA), Trastuzumab deruxtecan, Avutometinib (VS-6766) + defactinib, CTX131, AL3818, TOS-358, ²¹²Pb-DOTAM-GRPR1, Q702, BMS-986340, XB002, XmAb®23104, TG4001 + Avelumab, [225Ac]-FPI-1434 Injection, VMD-928, and others

Scope of the Cervical Cancer Market Report

  • Therapeutic Assessment: Cervical Cancer current marketed and emerging therapies
  • Cervical Cancer Market Dynamics: Attribute Analysis of Emerging Cervical Cancer Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Cervical Cancer Market Access and Reimbursement

Discover more about cervical cancer drugs in development @ Cervical Cancer Clinical Trials

Table of Contents

1. Cervical Cancer Market Key Insights
2. Cervical Cancer Market Report Introduction
3. Cervical Cancer Market Overview at a Glance
4. Cervical Cancer Market Executive Summary
5. Disease Background and Overview
6. Cervical Cancer Treatment and Management
7. Cervical Cancer Epidemiology and Patient Population
8. Patient Journey
9. Cervical Cancer Marketed Drugs
10. Cervical Cancer Emerging Drugs
11. Seven Major Cervical Cancer Market Analysis
12. Cervical Cancer Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Cervical Cancer Epidemiology Forecast

Cervical Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted cervical cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cervical Cancer Pipeline

Cervical Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cervical cancer companies, including Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene, MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories, Jiangsu Chia Tai Tianqing Pharmaceutical, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus, Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Genentech, among others.

Advanced Cervical Cancer Pipeline

Advanced Cervical Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced cervical cancer companies, including Akeso Biopharma, Hookipa Biotech GmbH, Biocad, Shanghai Henlius Biotech, Genexine, Inc., GlaxoSmithKline, EMD Serono, Zeria Pharmaceutical, Agenus Inc., Corregene Biotechnology Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nykode Therapeutics, Instil Bio, Fujifilm Pharmaceuticals U.S.A., Inc., Nurix Therapeutics, Inc., Bristol-Myers Squibb, NETRIS Pharma, Suzhou BlueHorse Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Adlai Nortye Biopharma Co., Ltd., SOTIO, Astex Pharmaceuticals, Inc., Rubius Therapeutics, Seagen Inc., Kymab Limited, Incyte Corporation, Ocellaris Pharma, Inc., among others.

Ovarian Cancer Pipeline

Ovarian Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including IMV, Elucida Oncology, Chia Tai Tianqing Pharmaceutical Group, Precigen, Inc, Glycotope GmbH, Sonnet Biotherapeutics, Allarity Therapeutics, Adimab, Mersana Therapeutics, Genentech, Genmab, Merck, OncoQuest, IMPACT Therapeutics, among others.

Advanced Ovarian Cancer Pipeline

Advanced Ovarian Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced ovarian cancer companies, including OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, among others.

Epithelial Ovarian Cancer Pipeline

Epithelial Ovarian Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epithelial ovarian cancer companies, including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co, Aravive Biologics, among others.

Other Trending Reports

Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

CONTACT: Contact Us Shruti Thakur  [email protected]  +1(919)321-6187  www.delveinsight.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.